Across TCGA pan-cancer cohorts, ZFP41 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ZFP41 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher ZFP41 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZFP41 expression acts as an unfavorable survival marker.
SARC are the cancer types where ZFP41 Mutation most reproducibly stratifies survival.